These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 33730837)

  • 21. Risk factors for the spread of vaccine-derived type 2 polioviruses after global withdrawal of trivalent oral poliovirus vaccine and the effects of outbreak responses with monovalent vaccine: a retrospective analysis of surveillance data for 51 countries in Africa.
    Cooper LV; Bandyopadhyay AS; Gumede N; Mach O; Mkanda P; Ndoutabé M; Okiror SO; Ramirez-Gonzalez A; Touray K; Wanyoike S; Grassly NC; Blake IM
    Lancet Infect Dis; 2022 Feb; 22(2):284-294. PubMed ID: 34648733
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polio endgame: the global introduction of inactivated polio vaccine.
    Patel M; Zipursky S; Orenstein W; Garon J; Zaffran M
    Expert Rev Vaccines; 2015 May; 14(5):749-62. PubMed ID: 25597843
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Virologic Monitoring of Poliovirus Type 2 after Oral Poliovirus Vaccine Type 2 Withdrawal in April 2016 - Worldwide, 2016-2017.
    Diop OM; Asghar H; Gavrilin E; Moeletsi NG; Benito GR; Paladin F; Pattamadilok S; Zhang Y; Goel A; Quddus A
    MMWR Morb Mortal Wkly Rep; 2017 May; 66(20):538-542. PubMed ID: 28542124
    [TBL] [Abstract][Full Text] [Related]  

  • 24. India's Preparedness for Introduction of IPV and Switch from tOPV to bOPV.
    Haldar P; Agrawal P
    Indian Pediatr; 2016 Aug; 53 Suppl 1():S44-S49. PubMed ID: 27771639
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vaccine-derived poliovirus serotype 2 outbreaks and response in the Democratic Republic of the Congo, 2017-2021.
    Alleman MM; Jorba J; Riziki Y; Henderson E; Mwehu A; Seakamela L; Howard W; Kadiobo Mbule A; Nsamba RN; Djawe K; Yapi MD; Mengouo MN; Gumede N; Ndoutabe M; Kfutwah AKW; Senouci K; Burns CC
    Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A35-A47. PubMed ID: 36907733
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Type 2 Poliovirus Detection after Global Withdrawal of Trivalent Oral Vaccine.
    Blake IM; Pons-Salort M; Molodecky NA; Diop OM; Chenoweth P; Bandyopadhyay AS; Zaffran M; Sutter RW; Grassly NC
    N Engl J Med; 2018 Aug; 379(9):834-845. PubMed ID: 30157398
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Experience With Inactivated Polio Vaccine Introduction and the "Switch" From Trivalent to Bivalent Oral Polio Vaccine in the World Health Organization's Western Pacific Region.
    Gurung S; Harris JB; Eltayeb AO; Hampton LM; Diorditsa S; Avagyan T; Schluter WW
    J Infect Dis; 2017 Jul; 216(suppl_1):S101-S108. PubMed ID: 28838170
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Eradicating polio: how the world's pediatricians can help stop this crippling illness forever.
    Orenstein WA;
    Pediatrics; 2015 Jan; 135(1):196-202. PubMed ID: 25548328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expected Implications of Globally Coordinated Cessation of Serotype 3 Oral Poliovirus Vaccine (OPV) Before Serotype 1 OPV.
    Kalkowska DA; Thompson KM
    Risk Anal; 2021 Feb; 41(2):312-319. PubMed ID: 32936466
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes.
    Thompson KM; Duintjer Tebbens RJ
    BMC Infect Dis; 2015 Sep; 15():374. PubMed ID: 26381878
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Polio Endgame, Information Gaps Related to Vaccines and Immunity.
    Ahmad M; Bahl S; Kunwar A
    Indian Pediatr; 2016 Aug; 53 Suppl 1():S33-S37. PubMed ID: 27771637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Introduction of Inactivated Poliovirus Vaccine and Trivalent Oral Polio Vaccine/Bivalent Oral Polio Vaccine Switch in the African Region.
    Tevi-Benissan C; Okeibunor J; du Châtellier GM; Assefa A; Biey JN; Cheikh D; Eshetu M; Anya BP; Dao H; Nasir Y; Akanmori BD; Mihigo R
    J Infect Dis; 2017 Jul; 216(suppl_1):S66-S75. PubMed ID: 28838178
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population Immunity against Serotype-2 Poliomyelitis Leading up to the Global Withdrawal of the Oral Poliovirus Vaccine: Spatio-temporal Modelling of Surveillance Data.
    Pons-Salort M; Molodecky NA; O'Reilly KM; Wadood MZ; Safdar RM; Etsano A; Vaz RG; Jafari H; Grassly NC; Blake IM
    PLoS Med; 2016 Oct; 13(10):e1002140. PubMed ID: 27701425
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Strategic Response to an Outbreak of Circulating Vaccine-Derived Poliovirus Type 2 - Syria, 2017-2018.
    Mbaeyi C; Wadood ZM; Moran T; ; Ather F; Stehling-Ariza T; Nikulin J; Al Safadi M; Iber J; Zomahoun L; Abourshaid N; Pang H; Collins N; Asghar H; Butt OUI; Burns CC; Ehrhardt D; Sharaf M
    MMWR Morb Mortal Wkly Rep; 2018 Jun; 67(24):690-694. PubMed ID: 29927908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine.
    Duintjer Tebbens RJ; Thompson KM
    Expert Rev Vaccines; 2018 Aug; 17(8):739-751. PubMed ID: 30056767
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity of New Primary Immunization Schedules With Inactivated Poliovirus Vaccine and Bivalent Oral Polio Vaccine for the Polio Endgame: A Review.
    Bandyopadhyay AS; Modlin JF; Wenger J; Gast C
    Clin Infect Dis; 2018 Oct; 67(suppl_1):S35-S41. PubMed ID: 30376081
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emerging challenges to realizing global polio eradication and their solutions.
    M A S
    East Mediterr Health J; 2022 Jul; 28(7):515-520. PubMed ID: 35959667
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs.
    Duintjer Tebbens RJ; Thompson KM
    BMC Infect Dis; 2015 Sep; 15():390. PubMed ID: 26404780
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lessons From Globally Coordinated Cessation of Serotype 2 Oral Poliovirus Vaccine for the Remaining Serotypes.
    Thompson KM; Duintjer Tebbens RJ
    J Infect Dis; 2017 Jul; 216(suppl_1):S168-S175. PubMed ID: 28838198
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Progress Toward Polio Eradication - Worldwide, January 2019-June 2021.
    Bigouette JP; Wilkinson AL; Tallis G; Burns CC; Wassilak SGF; Vertefeuille JF
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1129-1135. PubMed ID: 34437527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.